Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma von Suttle, A B, Ball, H A, Molimard, M, Hutson, T E, Carpenter, C, Rajagopalan, D, Lin, Y, Swann, S, Amado, R, Pandite, L

Volltext

Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinom... von Patil, S., Figlin, R.A., Hutson, T.E., Michaelson, M.D., Négrier, S., Kim, S.T., Huang, X., Motzer, R.J.

Volltext

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma von Motzer, R J, Escudier, B, Bukowski, R, Rini, B I, Hutson, T E, Barrios, C H, Lin, X, Fly, K, Matczak, E, Gore, M E

Volltext

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies en... von Calvo, E, Escudier, B, Motzer, R.J, Oudard, S, Hutson, T.E, Porta, C, Bracarda, S, Grünwald, V, Thompson, J.A, Ravaud, A, Kim, D, Panneerselvam, A, Anak, O, Figlin, R.A

Volltext

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial von Escudier, B, Michaelson, M D, Motzer, R J, Hutson, T E, Clark, J I, Lim, H Y, Porfiri, E, Zalewski, P, Kannourakis, G, Staehler, M, Tarazi, J, Rosbrook, B, Cisar, L, Hariharan, S, Kim, S, Rini, B I

Volltext

Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic c... von Sonpavde, G., Matveev, V., Burke, J.M., Caton, J.R., Fleming, M.T., Hutson, T.E., Galsky, M.D., Berry, W.R., Karlov, P., Holmlund, J.T., Wood, B.A., Brookes, M., Leopold, L.

Volltext

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis von Procopio, G, Bellmunt, J, Dutcher, J, Bracarda, S, Knox, J, Brueckner, A, Molnar, I, Escudier, B, Hutson, T E

Volltext

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma von Hutson, T E, Bukowski, R M, Rini, B I, Gore, M E, Larkin, J M, Figlin, R A, Barrios, C H, Escudier, B, Lin, X, Fly, K, Martell, B, Matczak, E, Motzer, R J

Volltext

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy von Sonpavde, G., Periman, P.O., Bernold, D., Weckstein, D., Fleming, M.T., Galsky, M.D., Berry, W.R., Zhan, F., Boehm, K.A., Asmar, L., Hutson, T.E.

Volltext

Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial von Zurita, A.J., George, D.J., Shore, N.D., Liu, G., Wilding, G., Hutson, T.E., Kozloff, M., Mathew, P., Harmon, C.S., Wang, S.L., Chen, I., Chow Maneval, E., Logothetis, C.J.

Volltext

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α von Patil, S, Figlin, R A, Hutson, T E, Michaelson, M D, Negrier, S, Kim, S T, Huang, X, Motzer, R J

Volltext

Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer von Choueiri, T. K., Mekhail, T., Hutson, T. E., Ganapathi, R., Kelly, G. E., Bukowski, R. M.

Volltext

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma von Zurita, A J, Gagnon, R C, Liu, Y, Tran, H T, Figlin, R A, Hutson, T E, D'Amelio Jr, A M, Sternberg, C N, Pandite, L N, Heymach, J V

Volltext

Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC):... von McDermott, D.F., Rini, B.I., Motzer, R.J., Tannir, N.M., Escudier, B., Kollmannsberger, C.K., Hammers, H.J., Porta, C., George, S., Donskov, F., Gurney, H.P., Grimm, M.-O., Harrison, M., Hutson, T.E., Doan, J., Yang, S., Rao, S., Mekan, S., Ambavane, A., Powles, T.

Volltext

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis von Bracarda, S, Hutson, T E, Porta, C, Figlin, R A, Calvo, E, Grünwald, V, Ravaud, A, Motzer, R, Kim, D, Anak, O, Panneerselvam, A, Escudier, B

Volltext

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-I subgroup analysis von BRACARDA, S, HUTSON, T. E, PANNEERSELVAM, A, ESCUDIER, B, PORTA, C, FIGLIN, R. A, CALVO, E, GRÜNWALD, V, RAVAUD, A, MOTZER, R, KIM, D, ANAK, O

Volltext

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma von Suttle, A B, Ball, H A, Molimard, M, Hutson, T E, Carpenter, C, Rajagopalan, D, Lin, Y, Swann, S, Amado, R, Pandite, L

Volltext

Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer von Galsky, M.D., Simon, K., Sonpavde, G., Hutson, T.E., Fleming, M., Kondagunta, G.V., Berry, W.

Volltext

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma von Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Mainwaring, Paul N, Rini, Brian I, Donskov, Frede, Hammers, Hans, Hutson, Thomas E, Lee, Jae-Lyun, Peltola, Katriina, Roth, Bruce J, Bjarnason, Georg A, Géczi, Lajos, Keam, Bhumsuk, Maroto, Pablo, Heng, Daniel Y.C, Schmidinger, Manuela, Kantoff, Philip W, Borgman-Hagey, Anne, Hessel, Colin, Scheffold, Christian, Schwab, Gisela M, Tannir, Nizar M, Motzer, Robert J

Volltext

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma von Motzer, Robert J, Hutson, Thomas E, Cella, David, Reeves, James, Hawkins, Robert, Guo, Jun, Nathan, Paul, Staehler, Michael, de Souza, Paul, Merchan, Jaime R, Boleti, Ekaterini, Fife, Kate, Jin, Jie, Jones, Robert, Uemura, Hirotsugu, De Giorgi, Ugo, Harmenberg, Ulrika, Wang, Jinwan, Sternberg, Cora N, Deen, Keith, McCann, Lauren, Hackshaw, Michelle D, Crescenzo, Rocco, Pandite, Lini N, Choueiri, Toni K

Volltext